- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07933042
A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.
Study Overview
Status
Conditions
Detailed Description
TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.
Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.
Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: TOBY ATLAS Study Team
- Phone Number: 309-592-8898
- Email: info@toby.health
Study Contact Backup
- Name: TOBY ATLAS Study Team
- Email: press@toby.health
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.
Description
Inclusion Criteria:
- Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
- Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
- Medical records available for the reference standard.
- Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.
Exclusion Criteria:
- Any exclusion stated in the applicable disease specification.
- Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
- Current pregnancy, imprisonment, or inability to consent for oneself (consented route).
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Target disease cases
Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified. |
|
Controls
Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical performance of each locked assay
Time Frame: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Paired comparison with available standard-of-care tests
Time Frame: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assay performance by subgroup and signal origin
Time Frame: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Protocol-conforming specimens with final reference-standard classification
Time Frame: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type. |
From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Candidate assays advanced to validation
Time Frame: From study start through study completion, estimated up to 5 years
|
Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan. |
From study start through study completion, estimated up to 5 years
|
|
Exploratory prognostic and simulated clinical and economic outcomes
Time Frame: Up to 5 years after specimen collection, where follow-up is permitted and available
|
Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care. |
Up to 5 years after specimen collection, where follow-up is permitted and available
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TOBY-ATLAS-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is currently no plan to make individual participant data available to other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.